Kwangmeyung Kim is an academic researcher from the Korea Institute of Science and Technology and a Distinguished Professor at the College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University. He obtained his B.Sc. at Sungkyunkwan University in Chemical Engineering in 1997, his M.Sc. at the Gwangju Institute of Science and Technology (GIST) in 1999, and his Ph.D. at the Gwangju Institute of Science and Technology (GIST) in 2003. He was awarded an “Excellent Research Scientist” by the Korea Institute of Science and Technology (KIST) in 2010, a “Prime Minister’s Commendation” by the Government of the Republic of Korea in 2013, and a “Medal of Honor in Science and Technology” by the Government of the Republic of Korea in 2019. His research interests focus on how theranostic biomaterials can be designed with tumor-specific fluorescence imaging probes, especially tumor-specifically activatable imaging probes, which in turn can be switched to therapeutic design with identical principles. He has an h-index of 87 and has co-authored more than 374 publications, receiving 26,416 citations (Scopus, November 2, 2023).
Short Biography
Kwangmeyung Kim is an academic researcher from the Korea Institute of Science and Technology and a Distinguished Professor at the College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University. He obtained his B.Sc. at Sungkyunkwan University in Chemical Engineering in 1997, his M.Sc. at the Gwangju Institute of Science and Technology (GIST) in 1999, and his Ph.D. at the Gwangju Institute of Science and Technology (GIST) in 2003. He was awarded an “Excellent Research Scientist” by the Korea Institute of Science and Technology (KIST) in 2010, a “Prime Minister’s Commendation” by the Government of the Republic of Korea in 2013, and a “Medal of Honor in Science and Technology” by the Government of the Republic of Korea in 2019. His research interests focus on how theranostic biomaterials can be designed with tumor-specific fluorescence imaging probes, especially tumor-specifically activatable imaging probes, which in turn can be switched to therapeutic design with identical principles. He has an h-index of 87 and has co-authored more than 374 publications, receiving 26,416 citations (Scopus, November 2, 2023).